42 58

Cited 0 times in

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial

DC FieldValueLanguage
dc.contributor.author김민환-
dc.contributor.author김현기-
dc.contributor.author김형일-
dc.contributor.author김효송-
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.contributor.author박형순-
dc.contributor.author범승훈-
dc.contributor.author손태일-
dc.contributor.author정민규-
dc.contributor.author정인경-
dc.contributor.author정재호-
dc.contributor.author정현철-
dc.contributor.author최윤영-
dc.contributor.author형우진-
dc.date.accessioned2019-09-20T07:43:42Z-
dc.date.available2019-09-20T07:43:42Z-
dc.date.issued2019-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171034-
dc.description.abstractPURPOSE: Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection. Materials and Methods: This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values. RESULTS: Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis. CONCLUSION: This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCancer Research and Treatment-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHB7-H1 Antigen/metabolism-
dc.subject.MESHBiomarkers, Tumor*-
dc.subject.MESHClinical Trials, Phase III as Topic-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHDNA-Binding Proteins/metabolism-
dc.subject.MESHEndonucleases/metabolism-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMulticenter Studies as Topic-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRandomized Controlled Trials as Topic-
dc.subject.MESHStomach Neoplasms/metabolism*-
dc.subject.MESHStomach Neoplasms/mortality*-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHStomach Neoplasms/therapy-
dc.titleImmunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMin Hwan Kim-
dc.contributor.googleauthorXianglan Zhang-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorInkyung Jung-
dc.contributor.googleauthorHyung Soon Park-
dc.contributor.googleauthorSeung-Hoon Beom-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorHyunki Kim-
dc.contributor.googleauthorYoon Young Choi-
dc.contributor.googleauthorTaeil Son-
dc.contributor.googleauthorHyoung-Il Kim-
dc.contributor.googleauthorJae-Ho Cheong-
dc.contributor.googleauthorWoo Jin Hyung-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorHyun Cheol Chung-
dc.identifier.doi10.4143/crt.2018.331-
dc.contributor.localIdA00482-
dc.contributor.localIdA01108-
dc.contributor.localIdA01108-
dc.contributor.localIdA01154-
dc.contributor.localIdA01154-
dc.contributor.localIdA01202-
dc.contributor.localIdA01202-
dc.contributor.localIdA01281-
dc.contributor.localIdA01281-
dc.contributor.localIdA01316-
dc.contributor.localIdA01316-
dc.contributor.localIdA04576-
dc.contributor.localIdA04576-
dc.contributor.localIdA04581-
dc.contributor.localIdA04581-
dc.contributor.localIdA01998-
dc.contributor.localIdA01998-
dc.contributor.localIdA03606-
dc.contributor.localIdA03606-
dc.contributor.localIdA03693-
dc.contributor.localIdA03693-
dc.contributor.localIdA03717-
dc.contributor.localIdA03717-
dc.contributor.localIdA03773-
dc.contributor.localIdA03773-
dc.contributor.localIdA04138-
dc.contributor.localIdA04138-
dc.contributor.localIdA04382-
dc.contributor.localIdA04382-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid30282452-
dc.subject.keywordBiomarkers-
dc.subject.keywordERCC1-
dc.subject.keywordPD-L1-
dc.subject.keywordPrognosis-
dc.subject.keywordStomach neoplasms-
dc.subject.keywordThymidylate synthase-
dc.contributor.alternativeNameKim, Min Hwan-
dc.contributor.affiliatedAuthor김민환-
dc.contributor.affiliatedAuthor김현기-
dc.contributor.affiliatedAuthor김현기-
dc.contributor.affiliatedAuthor김형일-
dc.contributor.affiliatedAuthor김형일-
dc.contributor.affiliatedAuthor김효송-
dc.contributor.affiliatedAuthor김효송-
dc.contributor.affiliatedAuthor노성훈-
dc.contributor.affiliatedAuthor노성훈-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor박형순-
dc.contributor.affiliatedAuthor박형순-
dc.contributor.affiliatedAuthor범승훈-
dc.contributor.affiliatedAuthor범승훈-
dc.contributor.affiliatedAuthor손태일-
dc.contributor.affiliatedAuthor손태일-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정인경-
dc.contributor.affiliatedAuthor정인경-
dc.contributor.affiliatedAuthor정재호-
dc.contributor.affiliatedAuthor정재호-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor최윤영-
dc.contributor.affiliatedAuthor최윤영-
dc.contributor.affiliatedAuthor형우진-
dc.contributor.affiliatedAuthor형우진-
dc.citation.volume51-
dc.citation.number2-
dc.citation.startPage819-
dc.citation.endPage831-
dc.identifier.bibliographicCitationCancer Research and Treatment, Vol.51(2) : 819-831, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.